Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.24
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Nov 30, 23 | Oppenheimer | maintain | Outperform | Outperform |
| Aug 22, 23 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Jul 18, 23 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| May 17, 23 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| May 17, 23 | Oppenheimer | maintain | Outperform | Outperform |
| Feb 14, 23 | Oppenheimer | maintain | Outperform | Outperform |
| Sep 28, 22 |
Daily · Wilder smoothing
| EF Hutton |
| maintain |
| Buy |
| Buy |
| Jul 22, 22 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Mar 17, 22 | EF Hutton | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 40.29 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 36.23 | Oscillator | Neutral |
| Williams %R (14) | -68.42 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.11 (Hist 0.01) | Oscillator | Buy |
| Average Directional Index (14) | 12.90 (+DI 23.4 / -DI 23.9) | Trend | Neutral |
| EMA 20 | 1.36 | MA | Strong Sell |
| SMA 20 | 1.34 | MA | Strong Sell |
| EMA 50 | 1.51 | MA | Strong Sell |
| SMA 50 | 1.63 | MA | Strong Sell |
| SMA 200 | 1.51 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 28, 26 | Palumbo Joseph M | officer: Chief Medical Officer | P-Purchase | 4,843 @ $2.16 | $10.46K |
| Aug 28, 26 | Chappell Amy Suzon | director | P-Purchase | 727 @ $2.16 | $1.57K |
| Aug 28, 26 | Kim Joanne Wendy | officer: Chief Financial Officer | P-Purchase | 2,500 @ $2.18 | $5.45K |
| Aug 27, 26 | Do Cuong V | director, officer: President & CEO | P-Purchase | 15,210 @ $2.08 | $31.64K |
| Jan 5, 26 | Palumbo Joseph M | officer: Chief Medical Officer | A-Award | 132,000 @ $1.31 | $172.9K |
| Jan 5, 26 | Kim Joanne Wendy | officer: Chief Financial Officer | A-Award | 110,100 @ $1.31 | $144.2K |
| Jan 5, 26 | Rogich Sigmund | director | A-Award | 141,100 @ $1.31 | $184.8K |
| Jan 5, 26 | Rogich Sigmund | director | A-Award | 70,000 @ $1.31 | $91.70K |
TTM vs. 5-year historical average (annual ratios)
| Metric | BIVI | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.4x | -1.2x · sector 20.7x | Discount |
| Forward P/E (FY27E) | -2.0x | EPS est. -0.63 | Elevated |
| Price / Book | 0.9x | 4.2x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.1x | 79553.8x | Discount |
| Return on equity | -126.0% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.03 | 0.94 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -39.40 | Distress |
Discounted cash flow model
Stock news · updated daily
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson's drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological Association's annual meeting in San Diego. The randomized, double-blind, placebo-controlled trial enrolled 57 patients, who received bezisterim or placebo for 12 weeks.
Parkinson's patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev.
| 4 | Aug 28, 2026 | 2026-08-28 21:01:49 | View |
| 4 | Aug 28, 2026 | 2026-08-28 21:01:21 | View |
| 4 | Aug 28, 2026 | 2026-08-28 20:58:13 | View |
| 4 | Aug 28, 2026 | 2026-08-28 20:57:40 | View |
| SC 13G | Aug 19, 2026 | 2026-08-19 16:08:40 | View |
| S-1/A | Aug 14, 2026 | 2026-08-14 17:23:15 | View |
Proxy statement (DEF 14A) disclosures
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its Phase 2 ADDRESS-LC trial found that bezisterim delivered the greatest benefits in Long COVID patients with more severe baseline fatigue, post-exertional malaise (PEM) or cognitive impairment, with statistically significant improvements across multiple measures. The results were presented at the American Neurological Association's annual meeting in San Diego, and the abstract was published in Annals of Neurology.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.52 | -0.70 | Miss -34.6% | — |
| May 11, 2026 | -0.73 | -0.70 | Beat 4.1% | — |
| Feb 10, 2026 | -0.81 | -0.77 | Beat 4.9% | — |
| Nov 10, 2025 | -0.79 | -0.98 | Miss -24.1% | — |
| Aug 15, 2025 | -1.82 | -1.82 | Beat 0.0% | — |
| May 12, 2025 | -3.20 | -1.50 | Beat 53.1% | — |